GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kaken Pharmaceutical Co Ltd (TSE:4521) » Definitions » EV-to-EBITDA

Kaken Pharmaceutical Co (TSE:4521) EV-to-EBITDA : 20.80 (As of May. 11, 2024)


View and export this data going back to 1961. Start your Free Trial

What is Kaken Pharmaceutical Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kaken Pharmaceutical Co's enterprise value is 円71,000 Mil. Kaken Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was 円3,414 Mil. Therefore, Kaken Pharmaceutical Co's EV-to-EBITDA for today is 20.80.

The historical rank and industry rank for Kaken Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:

TSE:4521' s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.38   Med: 6.79   Max: 21.73
Current: 20.79

During the past 13 years, the highest EV-to-EBITDA of Kaken Pharmaceutical Co was 21.73. The lowest was 3.38. And the median was 6.79.

TSE:4521's EV-to-EBITDA is ranked worse than
67.09% of 708 companies
in the Drug Manufacturers industry
Industry Median: 14.76 vs TSE:4521: 20.79

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), Kaken Pharmaceutical Co's stock price is 円3520.00. Kaken Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円78.043. Therefore, Kaken Pharmaceutical Co's PE Ratio for today is 45.10.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Kaken Pharmaceutical Co EV-to-EBITDA Historical Data

The historical data trend for Kaken Pharmaceutical Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kaken Pharmaceutical Co EV-to-EBITDA Chart

Kaken Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.36 4.37 4.41 4.69 7.30

Kaken Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.59 7.30 10.81 15.23 18.97

Competitive Comparison of Kaken Pharmaceutical Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Kaken Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaken Pharmaceutical Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kaken Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kaken Pharmaceutical Co's EV-to-EBITDA falls into.



Kaken Pharmaceutical Co EV-to-EBITDA Calculation

Kaken Pharmaceutical Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=71000.006/3414
=20.80

Kaken Pharmaceutical Co's current Enterprise Value is 円71,000 Mil.
Kaken Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円3,414 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kaken Pharmaceutical Co  (TSE:4521) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Kaken Pharmaceutical Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=3520.00/78.043
=45.10

Kaken Pharmaceutical Co's share price for today is 円3520.00.
Kaken Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円78.043.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Kaken Pharmaceutical Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kaken Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Kaken Pharmaceutical Co (TSE:4521) Business Description

Traded in Other Exchanges
Address
28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo, JPN, 1138650
Kaken Pharmaceutical Co is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Kaken Pharmaceutical Co (TSE:4521) Headlines

No Headlines